Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | How does olaparib affect the quality of life of breast cancer patients?

Elzbieta Senkus-Konefka • 8 Sep 2017
ESMO 2017
Breast Cancer Olaparib
OlympiA

The OlympiA study (NCT02032823) demonstrated the efficacy of olaparib in the treatment of breast cancer patients with germline BRCA 1/2 mutations. Here, Elzbieta Senkus-Konefka, MD, PhD from the Medical University of Gdansk, Gdansk, Poland discusses the effect that olaparib had on patient quality of life, an important factor in the treatment of cancer patients. This interview was recorded at the 2017 European Society for Medical Oncology (ESMO) conference held in Madrid, Spain.

More from Elzbieta Senkus-Konefka

4:13
What have we learned from recent clinical trials in early breast cancer treatment?
Elzbieta Senkus-Konefka • 21 Sep 2017
2:18
The importance of the OlympiA trial for breast cancer patients
Elzbieta Senkus-Konefka • 21 Sep 2017

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:03
The future of peptide-conjugated drugs in oncology
Mitchell Elliott • 8 Apr 2024
1:26
The clinical applications of MRD in breast cancer
Mitchell Elliott • 8 Apr 2024
1:47
CCNG1 as a biomarker for DRG-101 gene therapy in cancer
Vaishali Kumar • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals